Skip to content
2000
Volume 16, Issue 3
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

In the last decade, we have been developing some gold(III) derivatives showing interesting antitumor properties and reduced systemic and renal toxicity, compared to the clinically-established reference drug cisplatin. Starting from the rationale at the base of our investigations, this review has been divided into two sections, with respect to our patented first- (aminoderivatives) and secondgeneration (peptidomimetics) potential drugs. Every section describes the in vitro and in vivo anticancer activity of the compounds, chosen as models, towards different types of tumor. In particular, we summarize the results achieved so far, in particular taking into account the latest in-depth studies related to their activity, mechanism of action and toxicological profile. Taken together, our data could open up new prospects for further advanced preclinical pharmacological testing.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026615666150827094500
2016-01-01
2025-06-15
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026615666150827094500
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test